Progressive Multifocal Leukoencephalopathy Clinical Trial
Official title:
Role of Inflammation in PML
Verified date | August 2023 |
Source | Beth Israel Deaconess Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.
Status | Completed |
Enrollment | 126 |
Est. completion date | December 2018 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PML patients of 18 years of age or older will be included in this study. Exclusion Criteria: 1. Presence of opportunistic brain lesions other than PML. ( e.g., toxoplasmosis, lymphoma) 2. Presence of confounding neurological disorder such as brain neoplasm etc. In addition patients with a contraindication to MRI examination will be excluded from study. Contraindications to the MRI examination include: 1. Medically unstable or hematological, renal, or hepatic dysfunction. 2. Cardiac pacemaker 3. Internal clips, 4. Metal implants, or external clips with 10 mm of the head. 5. Metal in the eyes. 6. Pregnant 7. Claustrophobia |
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Beth Israel Deaconess Medical Center | National Institutes of Health (NIH) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02004444 -
JC Virus Reactivation in Multiple Sclerosis
|
N/A | |
Terminated |
NCT01211639 -
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
|
N/A | |
Recruiting |
NCT05849467 -
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
|
Phase 1 | |
Recruiting |
NCT01730131 -
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
|
||
Recruiting |
NCT04781309 -
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
|
Early Phase 1 | |
Completed |
NCT02694783 -
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
|
Early Phase 1 | |
Completed |
NCT03399981 -
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
|
||
Terminated |
NCT00746941 -
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
|
Phase 1/Phase 2 | |
Completed |
NCT02895581 -
Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy
|
N/A | |
Recruiting |
NCT04453917 -
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
|
N/A | |
Not yet recruiting |
NCT05541549 -
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
|
Phase 2 | |
Recruiting |
NCT04091932 -
Treatment of PD-1 Inhibitor in AIDS-associated PML
|
Phase 2 | |
Not yet recruiting |
NCT06276504 -
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
|
Phase 2/Phase 3 |